{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T20:37:53Z","timestamp":1792787873893,"version":"4.5.0"},"reference-count":45,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,6,27]],"date-time":"2026-06-27T00:00:00Z","timestamp":1782518400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T00:00:00Z","timestamp":1789516800000},"content-version":"vor","delay-in-days":81,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"PDS Biotechnology","id":[{"id":"https:\/\/ror.org\/05q1xcs51","id-type":"ROR","asserted-by":"crossref"}]},{"name":"National Institutes of Health Intramural Research Program","award":["ZIA BC011759"],"award-info":[{"award-number":["ZIA BC011759"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Cancer"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Adrenocortical carcinoma (ACC) is a rare, aggressive malignancy often detected at an advanced stage with limited effective treatment options beyond first-line chemotherapy. The liver is a common site of metastasis, and patients frequently present with substantial hepatic disease burden that precludes complete resection. Locoregional therapies, including hepatic artery infusion pump (HAIP) delivery of floxuridine, have not been thoroughly evaluated for treatment of ACC liver metastasis, likely due to its rare incidence and highly aggressive nature. PDS01ADC (previously referred to as NHS-IL12) is a novel antibody-drug conjugate designed to deliver the immunomodulatory cytokine interleukin-12 to areas of tumor necrosis and modulate the tumor microenvironment to support immune surveillance and cytotoxic tumor responses. Combination of PDS01ADC with HAIP therapy (HAIP-delivered floxuridine plus systemic chemotherapy) was recently found to be feasible for clinical evaluation by an interim analysis in patients with colorectal liver metastases. Patients who received PDS01ADC with HAIP therapy had extended overall survival compared to patients who received HAIP therapy alone in a nonrandomized prior sequential study. We discuss herein the rationale and initiation of a new clinical trial arm to evaluate HAIP therapy with PDS01ADC for patients with ACC liver metastasis who have failed standard of care therapy.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Patients with unresectable ACC liver metastasis and either resectable or no progressive extrahepatic disease will receive combination therapy including HAIP floxuridine and subcutaneous injection of PDS01ADC administered concurrently with systemic gemcitabine and oxaliplatin in 28-day cycles. The primary outcome measured is overall response rate as measured by Response Evaluation Criteria in Solid Tumors (RECIST v1.1) criteria. Secondary outcomes measured in this study include intrahepatic and extrahepatic progression-free survival, overall survival, and safety of PDS01ADC combination therapy with HAIP-delivered floxuridine.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Discussion<\/jats:title>\n                    <jats:p>For select patients with ACC liver metastasis, HAIP therapy with PDS01ADC may improve disease control and thereby prolong survival.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Trial registration<\/jats:title>\n                    <jats:p>\n                      Study ID NCT05286814 version 2026-05-04;\n                      <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" xlink:href=\"https:\/\/clinicaltrials.gov\/study\/NCT05286814\" ext-link-type=\"uri\">https:\/\/clinicaltrials.gov\/study\/NCT05286814<\/jats:ext-link>\n                      .\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12885-026-16425-0","type":"journal-article","created":{"date-parts":[[2026,6,27]],"date-time":"2026-06-27T12:46:54Z","timestamp":1782564414000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Study protocol: targeted delivery of interleukin-12 in combination with hepatic artery infusion pump therapy for patients with adrenocortical carcinoma liver metastases"],"prefix":"10.1186","volume":"26","author":[{"given":"Lindsay R.","family":"Friedman","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emily C.","family":"Smith","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A. Leila","family":"Sarvestani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alyssa V.","family":"Eade","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jason","family":"Ho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tracey","family":"Pu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carolina","family":"Larrain","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cathleen E.","family":"Hannah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tamika","family":"Magee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kathleen M.","family":"Smith","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Audra A.","family":"Satterwhite","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sophia","family":"Xiao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Justine F.","family":"Burke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Surajit","family":"Sinha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Priyanka P.","family":"Desai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kirsten","family":"Remmert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael J.","family":"Cavnar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James L.","family":"Gulley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey","family":"Schlom","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jaydira","family":"del Rivero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan M.","family":"Hernandez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,27]]},"reference":[{"issue":"5","key":"16425_CR1","doi-asserted-by":"publisher","first-page":"872","DOI":"10.1007\/s00268-005-0329-x","volume":"30","author":"E Kebebew","year":"2006","unstructured":"Kebebew E, Reiff E, Duh QY, Clark OH, McMillan A. Extent of disease at presentation and outcome for adrenocortical carcinoma: have we made progress? World J Surg. 2006;30(5):872\u20138.","journal-title":"World J Surg"},{"issue":"17","key":"16425_CR2","doi-asserted-by":"publisher","first-page":"1195","DOI":"10.1056\/NEJM199004263221705","volume":"322","author":"JP Luton","year":"1990","unstructured":"Luton JP, Cerdas S, Billaud L, Thomas G, Guilhaume B, Bertagna X, et al. Clinical features of adrenocortical carcinoma, prognostic factors, and the effect of mitotane therapy. N Engl J Med. 1990;322(17):1195\u2013201.","journal-title":"N Engl J Med"},{"issue":"1","key":"16425_CR3","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1016\/S0022-5347(05)64023-2","volume":"169","author":"L Ng","year":"2003","unstructured":"Ng L, Libertino JM. Adrenocortical carcinoma: diagnosis, evaluation and treatment. J Urol. 2003;169(1):5\u201311.","journal-title":"J Urol"},{"issue":"2","key":"16425_CR4","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1016\/j.beem.2008.10.008","volume":"23","author":"M Fassnacht","year":"2009","unstructured":"Fassnacht M, Allolio B. Clinical management of adrenocortical carcinoma. Best Pract Res Clin Endocrinol Metab. 2009;23(2):273\u201389.","journal-title":"Best Pract Res Clin Endocrinol Metab"},{"issue":"6","key":"16425_CR5","doi-asserted-by":"publisher","first-page":"619","DOI":"10.1053\/j.seminoncol.2010.10.011","volume":"37","author":"S Balasubramaniam","year":"2010","unstructured":"Balasubramaniam S, Fojo T. Practical considerations in the evaluation and management of adrenocortical cancer. Semin Oncol. 2010;37(6):619\u201326.","journal-title":"Semin Oncol"},{"issue":"23","key":"16425_CR6","doi-asserted-by":"publisher","first-page":"2189","DOI":"10.1056\/NEJMoa1200966","volume":"366","author":"M Fassnacht","year":"2012","unstructured":"Fassnacht M, Terzolo M, Allolio B, Baudin E, Haak H, Berruti A, et al. Combination chemotherapy in advanced adrenocortical carcinoma. N Engl J Med. 2012;366(23):2189\u201397.","journal-title":"N Engl J Med"},{"issue":"11","key":"16425_CR7","doi-asserted-by":"publisher","first-page":"1476","DOI":"10.1016\/j.annonc.2020.08.2099","volume":"31","author":"M Fassnacht","year":"2020","unstructured":"Fassnacht M, Assie G, Baudin E, Eisenhofer G, de la Fouchardiere C, Haak HR, et al. Adrenocortical carcinomas and malignant phaeochromocytomas: ESMO-EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2020;31(11):1476\u201390.","journal-title":"Ann Oncol"},{"issue":"5","key":"16425_CR8","doi-asserted-by":"publisher","first-page":"1457","DOI":"10.1007\/s00268-021-05957-0","volume":"45","author":"K Wu","year":"2021","unstructured":"Wu K, Liu Z, Li X, Lu Y. Adrenal Surgery for Synchronously Metastatic Adrenocortical Carcinoma: A Population-Based Analysis. World J Surg. 2021;45(5):1457\u201365.","journal-title":"World J Surg"},{"issue":"1","key":"16425_CR9","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1177\/000313481908500111","volume":"85","author":"WM Lo","year":"2019","unstructured":"Lo WM, Kariya CM, Hernandez JM. Operative Management of Recurrent and Metastatic Adrenocortical Carcinoma: A Systematic Review. Am Surg. 2019;85(1):23\u20138.","journal-title":"Am Surg"},{"issue":"7","key":"16425_CR10","doi-asserted-by":"publisher","first-page":"2650","DOI":"10.1210\/jc.2005-2730","volume":"91","author":"G Abiven","year":"2006","unstructured":"Abiven G, Coste J, Groussin L, Anract P, Tissier F, Legmann P, et al. Clinical and biological features in the prognosis of adrenocortical cancer: poor outcome of cortisol-secreting tumors in a series of 202 consecutive patients. J Clin Endocrinol Metab. 2006;91(7):2650\u20135.","journal-title":"J Clin Endocrinol Metab"},{"issue":"1","key":"16425_CR11","doi-asserted-by":"publisher","first-page":"522","DOI":"10.1186\/s12885-017-3506-z","volume":"17","author":"J Baur","year":"2017","unstructured":"Baur J, Buntemeyer TO, Megerle F, Deutschbein T, Spitzweg C, Quinkler M, et al. Outcome after resection of Adrenocortical Carcinoma liver metastases: a retrospective study. BMC Cancer. 2017;17(1):522.","journal-title":"BMC Cancer"},{"issue":"1","key":"16425_CR12","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1016\/j.soc.2015.08.011","volume":"25","author":"J Datta","year":"2016","unstructured":"Datta J, Roses RE. Surgical Management of Adrenocortical Carcinoma: An Evidence-Based Approach. Surg Oncol Clin N Am. 2016;25(1):153\u201370.","journal-title":"Surg Oncol Clin N Am"},{"issue":"2","key":"16425_CR13","doi-asserted-by":"publisher","first-page":"282","DOI":"10.1210\/er.2013-1029","volume":"35","author":"T Else","year":"2014","unstructured":"Else T, Kim AC, Sabolch A, Raymond VM, Kandathil A, Caoili EM, et al. Adrenocortical carcinoma. Endocr Rev. 2014;35(2):282\u2013326.","journal-title":"Endocr Rev"},{"issue":"6","key":"16425_CR14","doi-asserted-by":"publisher","first-page":"1531","DOI":"10.1016\/j.surg.2014.08.047","volume":"156","author":"M Livhits","year":"2014","unstructured":"Livhits M, Li N, Yeh MW, Harari A. Surgery is associated with improved survival for adrenocortical cancer, even in metastatic disease. Surgery. 2014;156(6):1531\u201340. discussion 40\u20131.","journal-title":"Surgery"},{"issue":"2","key":"16425_CR15","doi-asserted-by":"publisher","first-page":"161","DOI":"10.2217\/ije-2015-0003","volume":"3","author":"LA McDuffie","year":"2016","unstructured":"McDuffie LA, Aufforth RD. Adrenocortical carcinoma: modern management and evolving treatment strategies. Int J Endocr Oncol. 2016;3(2):161\u201374.","journal-title":"Int J Endocr Oncol"},{"issue":"5","key":"16425_CR16","doi-asserted-by":"publisher","first-page":"438","DOI":"10.1016\/S2213-8587(24)00378-4","volume":"13","author":"M Fassnacht","year":"2025","unstructured":"Fassnacht M, Puglisi S, Kimpel O, Terzolo M. Adrenocortical carcinoma: a practical guide for clinicians. Lancet Diabetes Endocrinol. 2025;13(5):438\u201352.","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"8","key":"16425_CR17","doi-asserted-by":"publisher","first-page":"2643","DOI":"10.1245\/s10434-012-2358-7","volume":"19","author":"S Gaujoux","year":"2012","unstructured":"Gaujoux S, Al-Ahmadie H, Allen PJ, Gonen M, Shia J, D\u2019Angelica M, et al. Resection of adrenocortical carcinoma liver metastasis: is it justified? Ann Surg Oncol. 2012;19(8):2643\u201351.","journal-title":"Ann Surg Oncol"},{"issue":"7","key":"16425_CR18","doi-asserted-by":"publisher","first-page":"1972","DOI":"10.1245\/s10434-011-1564-z","volume":"18","author":"RT Ripley","year":"2011","unstructured":"Ripley RT, Kemp CD, Davis JL, Langan RC, Royal RE, Libutti SK, et al. Liver resection and ablation for metastatic adrenocortical carcinoma. Ann Surg Oncol. 2011;18(7):1972\u20139.","journal-title":"Ann Surg Oncol"},{"issue":"1","key":"16425_CR19","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1016\/j.hpb.2019.07.002","volume":"22","author":"RI Ayabe","year":"2020","unstructured":"Ayabe RI, Narayan RR, Ruff SM, Wach MM, Lo W, Nierop PMH, et al. Disease-free interval and tumor functional status can be used to select patients for resection\/ablation of liver metastases from adrenocortical carcinoma: insights from a multi-institutional study. HPB (Oxford). 2020;22(1):169\u201375.","journal-title":"HPB (Oxford)"},{"issue":"6","key":"16425_CR20","doi-asserted-by":"publisher","first-page":"4357","DOI":"10.3390\/curroncol28060370","volume":"28","author":"SN Fuller","year":"2021","unstructured":"Fuller SN, Shafiei A, Venzon DJ, Liewehr DJ, Mauda Havanuk M, Ilanchezhian MG, et al. Tumor Doubling Time Using CT Volumetric Segmentation in Metastatic Adrenocortical Carcinoma. Curr Oncol. 2021;28(6):4357\u201366.","journal-title":"Curr Oncol"},{"issue":"3","key":"16425_CR21","doi-asserted-by":"publisher","first-page":"554","DOI":"10.1002\/cncr.11084","volume":"97","author":"BJ Wood","year":"2003","unstructured":"Wood BJ, Abraham J, Hvizda JL, Alexander HR, Fojo T. Radiofrequency ablation of adrenal tumors and adrenocortical carcinoma metastases. Cancer. 2003;97(3):554\u201360.","journal-title":"Cancer"},{"issue":"7","key":"16425_CR22","doi-asserted-by":"publisher","first-page":"2259","DOI":"10.1002\/cam4.3740","volume":"10","author":"M Mauda-Havakuk","year":"2021","unstructured":"Mauda-Havakuk M, Levin E, Levy EB, Krishnasamy VP, Anderson V, Jain N, et al. Long-term outcomes in patients with advanced adrenocortical carcinoma after image-guided locoregional ablation or embolization. Cancer Med. 2021;10(7):2259\u201367.","journal-title":"Cancer Med"},{"issue":"8","key":"16425_CR23","doi-asserted-by":"publisher","first-page":"bvac091","DOI":"10.1210\/jendso\/bvac091","volume":"6","author":"TY Lin","year":"2022","unstructured":"Lin TY, Lin KY, Kuo HY, Huang KH, Wang CY, Lin YL, et al. Yttrium-90 Selective Internal Radiation Therapy Plus Cryoablation for Recurrent Adrenocortical Carcinoma With Liver Metastases. J Endocr Soc. 2022;6(8):bvac091.","journal-title":"J Endocr Soc"},{"issue":"1","key":"16425_CR24","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1159\/000504779","volume":"13","author":"N Pigg","year":"2020","unstructured":"Pigg N, Aboubechara D, Fourzali R, Baigorri B. Yttrium-90 Radioembolization of Metastatic Adrenocortical Carcinoma to the Liver following Systemic Chemotherapy and Surgical Resection of the Primary Lesion. Case Rep Oncol. 2020;13(1):158\u201363.","journal-title":"Case Rep Oncol"},{"issue":"1","key":"16425_CR25","doi-asserted-by":"publisher","first-page":"20","DOI":"10.5306\/wjco.v9.i1.20","volume":"9","author":"MS Makary","year":"2018","unstructured":"Makary MS, Krishner LS, Wuthrick EJ, Bloomston MP, Dowell JD. Yttrium-90 microsphere selective internal radiation therapy for liver metastases following systemic chemotherapy and surgical resection for metastatic adrenocortical carcinoma. World J Clin Oncol. 2018;9(1):20\u20135.","journal-title":"World J Clin Oncol"},{"issue":"27","key":"16425_CR26","doi-asserted-by":"publisher","first-page":"2039","DOI":"10.1056\/NEJM199912303412702","volume":"341","author":"N Kemeny","year":"1999","unstructured":"Kemeny N, Huang Y, Cohen AM, Shi W, Conti JA, Brennan MF, et al. Hepatic arterial infusion of chemotherapy after resection of hepatic metastases from colorectal cancer. N Engl J Med. 1999;341(27):2039\u201348.","journal-title":"N Engl J Med"},{"issue":"5","key":"16425_CR27","doi-asserted-by":"publisher","first-page":"477","DOI":"10.1002\/jso.24189","volume":"113","author":"NE Kemeny","year":"2016","unstructured":"Kemeny NE, Chou JF, Boucher TM, Capanu M, DeMatteo RP, Jarnagin WR, et al. Updated long-term survival for patients with metastatic colorectal cancer treated with liver resection followed by hepatic arterial infusion and systemic chemotherapy. J Surg Oncol. 2016;113(5):477\u201384.","journal-title":"J Surg Oncol"},{"issue":"9","key":"16425_CR28","doi-asserted-by":"publisher","first-page":"1395","DOI":"10.1200\/JCO.2005.03.8166","volume":"24","author":"NE Kemeny","year":"2006","unstructured":"Kemeny NE, Niedzwiecki D, Hollis DR, Lenz HJ, Warren RS, Naughton MJ, et al. Hepatic arterial infusion versus systemic therapy for hepatic metastases from colorectal cancer: a randomized trial of efficacy, quality of life, and molecular markers (CALGB 9481). J Clin Oncol. 2006;24(9):1395\u2013403.","journal-title":"J Clin Oncol"},{"issue":"5","key":"16425_CR29","first-page":"969","volume":"30","author":"C Breedis","year":"1954","unstructured":"Breedis C, Young G. The blood supply of neoplasms in the liver. Am J Pathol. 1954;30(5):969\u201377.","journal-title":"Am J Pathol"},{"issue":"3","key":"16425_CR30","doi-asserted-by":"publisher","first-page":"621","DOI":"10.1148\/radiology.187.3.8497606","volume":"187","author":"Z Kan","year":"1993","unstructured":"Kan Z, Ivancev K, Lunderquist A, McCuskey PA, Wright KC, Wallace S, et al. In vivo microscopy of hepatic tumors in animal models: a dynamic investigation of blood supply to hepatic metastases. Radiology. 1993;187(3):621\u20136.","journal-title":"Radiology"},{"issue":"4","key":"16425_CR31","first-page":"589","volume":"75","author":"NB Ackerman","year":"1974","unstructured":"Ackerman NB. The blood supply of experimental liver metastases. IV. Changes in vascularity with increasing tumor growth. Surgery. 1974;75(4):589\u201396.","journal-title":"Surgery"},{"issue":"11 Pt 1","key":"16425_CR32","first-page":"3784","volume":"38","author":"WD Ensminger","year":"1978","unstructured":"Ensminger WD, Rosowsky A, Raso V, Levin DC, Glode M, Come S, et al. A clinical-pharmacological evaluation of hepatic arterial infusions of 5-fluoro-2\u2019-deoxyuridine and 5-fluorouracil. Cancer Res. 1978;38(11 Pt 1):3784\u201392.","journal-title":"Cancer Res"},{"issue":"12","key":"16425_CR33","doi-asserted-by":"publisher","first-page":"2997","DOI":"10.1002\/1097-0142(19910615)67:12<2997::AID-CNCR2820671211>3.0.CO;2-#","volume":"67","author":"M Schlumberger","year":"1991","unstructured":"Schlumberger M, Brugieres L, Gicquel C, Travagli JP, Droz JP, Parmentier C. 5-Fluorouracil, doxorubicin, and cisplatin as treatment for adrenal cortical carcinoma. Cancer. 1991;67(12):2997\u20133000.","journal-title":"Cancer"},{"issue":"11","key":"16425_CR34","doi-asserted-by":"publisher","first-page":"1446","DOI":"10.1016\/j.hpb.2023.06.014","volume":"25","author":"HG McDonald","year":"2023","unstructured":"McDonald HG, Sarvestani AL, Owen JW, Rueckert J, Wierman ME, Kiseljak-Vassiliades K, et al. Response of adrenocortical carcinoma liver metastases to hepatic artery infusion floxuridine. HPB (Oxford). 2023;25(11):1446\u20139.","journal-title":"HPB (Oxford)"},{"key":"16425_CR35","doi-asserted-by":"crossref","unstructured":"Ababneh O, Ghazou A, Alawajneh M, Alhaj Mohammad S, Bani-Hani A, Alrabadi N et al. The Efficacy and Safety of Immune Checkpoint Inhibitors in Adrenocortical Carcinoma: A Systematic Review and Meta-Analysis. Cancers (Basel). 2024;16(5).","DOI":"10.3390\/cancers16050900"},{"issue":"Suppl","key":"16425_CR36","doi-asserted-by":"publisher","first-page":"S16","DOI":"10.1007\/s002800051031","volume":"38","author":"MJ Brunda","year":"1996","unstructured":"Brunda MJ, Luistro L, Rumennik L, Wright RB, Dvorozniak M, Aglione A, et al. Antitumor activity of interleukin 12 in preclinical models. Cancer Chemother Pharmacol. 1996;38(Suppl):S16\u201321.","journal-title":"Cancer Chemother Pharmacol"},{"issue":"8","key":"16425_CR37","doi-asserted-by":"publisher","first-page":"682","DOI":"10.2174\/1568009617666170427102729","volume":"17","author":"X Lu","year":"2017","unstructured":"Lu X. Impact of IL-12 in Cancer. Curr Cancer Drug Targets. 2017;17(8):682\u201397.","journal-title":"Curr Cancer Drug Targets"},{"issue":"11","key":"16425_CR38","doi-asserted-by":"publisher","first-page":"1030","DOI":"10.1038\/ni.1947","volume":"11","author":"M Eisenring","year":"2010","unstructured":"Eisenring M, vom Berg J, Kristiansen G, Saller E, Becher B. IL-12 initiates tumor rejection via lymphoid tissue-inducer cells bearing the natural cytotoxicity receptor NKp46. Nat Immunol. 2010;11(11):1030\u20138.","journal-title":"Nat Immunol"},{"issue":"3","key":"16425_CR39","first-page":"409","volume":"3","author":"MB Atkins","year":"1997","unstructured":"Atkins MB, Robertson MJ, Gordon M, Lotze MT, DeCoste M, DuBois JS, et al. Phase I evaluation of intravenous recombinant human interleukin 12 in patients with advanced malignancies. Clin Cancer Res. 1997;3(3):409\u201317.","journal-title":"Clin Cancer Res"},{"key":"16425_CR40","doi-asserted-by":"crossref","unstructured":"Greiner JW, Morillon YM 2nd, Schlom J. NHS-IL12, a Tumor-Targeting Immunocytokine. Immunotargets Ther. 2021;10:155\u201369.","DOI":"10.2147\/ITT.S306150"},{"key":"16425_CR41","doi-asserted-by":"crossref","unstructured":"Toney NJ, Gatti-Mays ME, Tschernia NP, Strauss J, Gulley JL, Schlom J et al. Immune correlates with response in patients with metastatic solid tumors treated with a tumor targeting immunocytokine NHS-IL12. Int Immunopharmacol. 2023;116.","DOI":"10.1016\/j.intimp.2023.109736"},{"issue":"1","key":"16425_CR42","doi-asserted-by":"publisher","first-page":"e2500173","DOI":"10.1200\/OA-25-00173","volume":"3","author":"AV Eade","year":"2026","unstructured":"Eade AV, Smith EC, Monge C, Hannah CE, Skorupan N, Hrones DM, et al. Tumor-Targeted IL-12 (PDS01ADC) with Hepatic Artery Infusion Pump Therapy for Colorectal Liver Metastases: Interim Analysis of a Non-randomized Phase II Trial. JCO Oncol Adv. 2026;3(1):e2500173.","journal-title":"JCO Oncol Adv"},{"issue":"3","key":"16425_CR43","doi-asserted-by":"publisher","first-page":"1348","DOI":"10.21037\/jgo-24-71","volume":"15","author":"JH Victory","year":"2024","unstructured":"Victory JH, Smith EC, Ryan CE, Lambdin J, Sarvestani AL, Friedman LR, et al. Hepatic artery infusion pump (HAIP) therapy in combination with targeted delivery of IL-12 for patients with metastatic colorectal cancer or intrahepatic cholangiocarcinoma: a phase II trial protocol. J Gastrointest Oncol. 2024;15(3):1348\u201354.","journal-title":"J Gastrointest Oncol"},{"issue":"1","key":"16425_CR44","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1158\/1078-0432.CCR-18-1512","volume":"25","author":"J Strauss","year":"2019","unstructured":"Strauss J, Heery CR, Kim JW, Jochems C, Donahue RN, Montgomery AS, et al. First-in-Human Phase I Trial of a Tumor-Targeted Cytokine (NHS-IL12) in Subjects with Metastatic Solid Tumors. Clin Cancer Res. 2019;25(1):99\u2013109.","journal-title":"Clin Cancer Res"},{"issue":"7","key":"16425_CR45","doi-asserted-by":"publisher","first-page":"1869","DOI":"10.18632\/oncotarget.1853","volume":"5","author":"J Fallon","year":"2014","unstructured":"Fallon J, Tighe R, Kradjian G, Guzman W, Bernhardt A, Neuteboom B, et al. The immunocytokine NHS-IL12 as a potential cancer therapeutic. Oncotarget. 2014;5(7):1869\u201384.","journal-title":"Oncotarget"}],"container-title":["BMC Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12885-026-16425-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-026-16425-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-026-16425-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T23:38:02Z","timestamp":1789515482000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12885-026-16425-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,27]]},"references-count":45,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["16425"],"URL":"https:\/\/doi.org\/10.1186\/s12885-026-16425-0","relation":{},"ISSN":["1471-2407"],"issn-type":[{"value":"1471-2407","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,27]]},"assertion":[{"value":"6 April 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 June 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 June 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors are accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved. The study was conducted in accordance with the Declaration of Helsinki (as revised in 2013) and was approved by the National Cancer Institute Institutional Review Board, approval numbers 000307C (NCT05286814), 13-C-0176, and 04-C-0165.","order":1,"name":"Ethics","label":"Ethics approval and consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Written informed consent obtained from all patients for their participation and for publication of their de-identified data.","order":2,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Drs. Gulley and Schlom are the Principal Investigators on a Collaborative Research and Development Agreement between the National Cancer Institute and PDS Biotechnology. No other disclosures were reported.","order":3,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"1099"}}